Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.82 |
| ▸ | EHMT2 | Q96KQ7 | 13/20 | 0.57 |
| ▸ | EP300 | Q09472 | 6/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.57 |
| ▸ | SUV39H1 | O43463 | 4/20 | 0.57 |
| ▸ | NSD2 | O96028 | 1/20 | 0.57 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.57 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.57 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.57 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.37 |
| ▸ | RNF31 | Q96EP0 | 1/20 | 0.37 |
| ▸ | RBCK1 | Q9BYM8 | 1/20 | 0.37 |
| ▸ | SHARPIN | Q9H0F6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Verticillin B SCHEMBL17975438 | 1.00 | KMT2A (0.82) | KMT2AEHMT2EP300HIF1ASUV39H1 | |
| Verticillin B SCHEMBL21497282 | 1.00 | KMT2A (0.82) | KMT2AEHMT2EP300HIF1ASUV39H1 | |
| Melinacidin Iv SCHEMBL30713080 | 0.96 | KMT2A (0.74) | KMT2AEHMT2EP300HIF1ASUV39H1 | |
| Melinacidin Iv SCHEMBL19275171 | 0.96 | KMT2A (0.74) | KMT2AEHMT2EP300HIF1ASUV39H1 | |
| SCHEMBL29623437 | 0.92 | KMT2A (0.82) | KMT2AEHMT2EP300HIF1ASUV39H1 | |
| SCHEMBL19275302 | 0.91 | KMT2A (0.81) | KMT2AEHMT2EP300HIF1ASUV39H1 | |
| Verticillin A SCHEMBL18294765 | 0.91 | KMT2A (1.00) | KMT2AEHMT2EP300HIF1ASUV39H1 | |
| Verticillin A SCHEMBL29623144 | 0.91 | KMT2A (1.00) | KMT2AEHMT2EP300HIF1ASUV39H1 | |
| Verticillin A SCHEMBL19275238 | 0.91 | KMT2A (1.00) | KMT2AEHMT2EP300HIF1ASUV39H1 | |
| Verticillin A SCHEMBL15791200 | 0.91 | KMT2A (1.00) | KMT2AEHMT2EP300HIF1ASUV39H1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012161799-A1 | EPIDITHIODIOXOPIPERAZINES AND USES THEREOF IN TREATING CANCER | GEORGIA HEALTH SCIENCES UNIVERSITY RESEARCH INSTITUTE, INC (US) | 2012-11-29 | — | — | WO | claimed |
| US-20120219568-A1 | EPIDITHIODIOXOPIPRAZINES AND USES THEREOF IN TREATING CANCER | ZHEJIANG UNIVERSITY | 2012-08-30 | — | — | US | claimed |
| WO-2012161799-A1 | EPIDITHIODIOXOPIPERAZINES AND USES THEREOF IN TREATING CANCER | GEORGIA HEALTH SCIENCES UNIVERSITY RESEARCH INSTITUTE, INC (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120219568-A1 | EPIDITHIODIOXOPIPRAZINES AND USES THEREOF IN TREATING CANCER | ZHEJIANG UNIVERSITY | 2012-08-30 | — | — | US | disclosed |
| US-20060068460-A1 | Biochemical synthesis apparatus | BIODIVERSITY LIMITED | 2006-03-30 | — | — | US | disclosed |
| US-6991919-B1 | Biochemical synthesis apparatus | BIODIVERSITY LIMITED (GB) | 2006-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120219568-A1 | EPIDITHIODIOXOPIPRAZINES AND USES THEREOF IN TREATING CANCER | TOP2A, EI24, BAD | KMT2A 3006/4885EHMT2 2639/4885EP300 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.